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1. Introduction 
Cervical cancer is the third most commonly diagnosed cancer in women worldwide (Ferlay, 
Shin et al. 2010) and is a result of infection with cancer-causing types of human 
papillomavirus (HPV) (Bouvard, Baan et al. 2009). HPV is a very common infection, 
although in most circumstances, infection does not usually result in cervical disease (Trottier 
and Franco 2006). In fact, the natural history of HPV infection suggests that additional 
factors are required to drive progression from infection to the development of cancer. Most 
women are thought to clear their HPV infections within two years, but in approximately 
10% of women, infection persists (Schiffman, Castle et al. 2007). Persistent HPV infection is, 
in effect, the strongest risk factor for progression to cervical precancer and cancer (Koshiol, 
Lindsay et al. 2008), and a dysfunctional immune response is likely to underlie the amplified 
risk that leads to HPV persistence and cervical cancer. Although efficacious prophylactic 
vaccines against the two types of HPV (16 and 18) that cause about 70% of cervical cancers 
(Munoz, Castellsague et al. 2006) are available, these vaccines are expensive, difficult to 
administer in poorer countries and will not protect women who have already been exposed 
to the virus (FUTURE II Study Group 2007; Hildesheim, Herrero et al. 2007) (Su, Wu et al. 
2010). Thus, it is important to understand factors that predispose some women infected with 
a carcinogenic HPV infection to persist and progress.  
HPV uses a variety of methods to avoid immune detection, such as maintaining an 
unobtrusive infectious cycle (e.g., non-viremic and non-cytolytic since replication occurs in 
cells already destined for natural cell death), suppressing interferon response, and down-
regulating toll-like receptor (TLR)-9 (Stanley 2010). By employing such immune evasion 
tactics, HPV infection itself does not lead to a direct or obvious inflammatory response. 
Rather, inflammation due to other co-factors such as smoking, parity, oral contraceptive use, 
co-infection with other sexually transmitted diseases, multiple sexual partners etc. have long 
been hypothesized to lead to HPV incidence, persistence, and progression to cervical pre-
cancer and cancer (Castle and Giuliano 2003). Studies that directly evaluate women’s 
immune response to HPV infection may provide better insights into the role of 
inflammation and immunity in HPV persistence and cervical carcinogenesis.  
Although humoral response to HPV infection has been well-characterized (Bhat, Mattarollo et 
al. 2011), cell-mediated response has not been well established. Numerous approaches have 
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been used to characterize cell-mediated immune responses to HPV. Such approaches include 
measurement of cytokines and other immune markers that commonly lead to infiltration of 
immune cells. Cytokines are pleiotropic glycoproteins that regulate cell survival, proliferation, 
differentiation and activation at both local and systemic levels. During inflammation, their 
excessive release may lead to both chronicity and pathogenicity. The purpose of this review is 
to describe the current state of knowledge regarding these important regulators or other 
important immune markers of cell-mediated immune response in HPV infection. To this end, 
we have evaluated studies in plasma or serum from peripheral blood, in cervical secretions, in 
unstimulated and stimulated PBMCs (and cellular subsets thereof),  and in cervical tissues 
themselves.  Importantly, this chapter will highlight not only the large amount of knowledge 
gained from these studies, but also the many scientific gaps in knowledge that remain. 
2. Methods 
Relevant studies were identified by searching MEDLINE (via PubMed) using broad search 
term categories for cervix and immunity (Appendix 1). The search included studies 
identified through 3 November 2011. Studies that evaluated cell-mediated immune response 
immune response by HPV status (positivity, persistence, or clearance) were included if there 
were at least 10 women in each comparison group (usually HPV-positive versus HPV-
negative; sometime HPV persistence versus clearance or difference by HPV type). To focus 
on more functional aspects of immune response, only studies of immune-related proteins 
and mRNA (evidence of expression) and studies with HPV DNA detection were included. 
Studies were excluded if the HPV status and disease status of the referent group was 
unclear or if they focused on DNA polymorphisms alone. Given the focus on HPV infection, 
studies were also excluded if they include cervical cancer patients, but no other groups [i.e. 
normal women, women with low-grade squamous intraepithelial lesions (LSIL) or cervical 
intraepithelial neoplasia (CIN)]. Studies that included some cervical cancer patients along 
with CIN or normal patients were retained. Post-treatment studies or studies involving 
mice, cell lines, or HPV at extra-cervical anatomical sites were excluded as well.  
Data were abstracted on the study characteristics, HPV measurement, immune marker 
measurement, and results pertinent to this review. Study characteristics included the 
country in which the study was conducted, the method of cervical secretion collection, and 
descriptions of comparison groups relevant for this review (e.g., women with incident HPV 
versus no HPV). The assay used to detect HPV was also noted. Immune marker-related data 
included the assay used to measure the immune marker and the specific markers measured, 
along with the results. Approximately 50% of studies were double abstracted. 
3. Literature review 
In total, 35 studies met our inclusion criteria. These studies fell into four broad categories 
(Tables 1 to 4): circulating immune markers in plasma or serum (N = 7), those secreted 
locally in the cervix (N = 7), immune responses in patient-derived PBMCs (N = 10), and 
tissue-based immune markers (N = 12). One study contributed to both the circulating and 
PBMC-based immune marker categories. 
Circulating Immune Markers in Plasma/Serum. Cytokines and soluble immune markers are 
increasingly being measured in readily accessible plasma and serum in the hope that they will 
provide useful diagnostic and prognostic information, as well as insight into the pathogenesis 
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of numerous diseases. Further, the availability of inexpensive enzyme-linked immunosorbent 
assays (ELISAs), radioimmunoassays (RIAs), and other bioassays to reliably measure 
cytokines in these samples make them enticing targets for discovery. Currently, seven studies 
that met our inclusion criteria have directly examined HPV-infection-related immune 
responses in either serum or plasma (Table 1). All of these studies have focused on associations 
with carcinogenic infection using a Hybrid Capture assay. Hildesheim et al. (Hildesheim, 
Schiffman et al. 1997) was among the first to use plasma to evaluate markers of immunity. 
However, their comparison of carcinogenic HPV positive women with low-grade lesions to 
carcinogenic negative women with low-grade lesions failed to find a statistical difference in 
the soluble IL-2 receptor (sIL-2R; p=0.63). Adam et al. (Adam, Horowitz et al. 1999) similarly 
compared 10 women with high risk HPV infection to 10 HPV negative women and reported 
that high risk HPV infection was indeed associated with higher mean serum CSF-1 levels. 
Abike et al. (Abike, Engin et al. 2011) measured neopterin, often considered a marker of 
immune activation, and found lower concentrations in HPV-positive versus HPV-negative 
women with normal through high-grade histology.  Unlike the earlier studies, Bais et al. (Bais 
2005) measured numerous cytokines simultaneously (IL-2, IL-4, IL-10, IL-12, IFN-Ǆ, TNF-ǂ), as 
well as soluble markers (sTNFRI and sTNFRII) in plasma. They discovered that higher mean 
IL-2 levels alone were associated with carcinogenic HPV positivity. Baker et al. (Baker, Dauner 
et al. 2011) evaluated eleven circulating markers  (adiponectin, resistin, tPAI-1,  HGF, TNF-ǂ, 
leptin, IL-8, sVCAM-1, sICAM-1, sFas, MIF) and found elevated levels of resistin [odds 
ratio(OR) for 3rd versus 1st tertile, 103.3; 95 confidence interval (CI),  19.3–552.8; P < 0.0001], 
sFas (OR, 4.2; 95% CI, 1.5–11.7; P = 0.003), IL-8 (OR, 59.8; 95% CI, 11.4–312.5; P < 0.0001), and 
TNA-ǂ (OR, 38.6; 95% CI,  9.1–164.3, P < 0.0001) were in women with persistent HPV infection 
compared to HPV-negative women. Kemp et al. (Kemp, Hildesheim et al. 2010) evaluated an 
even broader spectrum of cytokines in their comparison of 50 HPV-positive women older than 
45 years and 50 HPV-negative similarly aged women from their population-based cohort 
study in Guanacaste, Costa Rica.  Plasma levels of IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, 
IL-1ǂ, IFN-Ǆ, GM-CSF, TNF-ǂ, MCP-1, MIP-1ǂ, IP-10, RANTES, eotaxin, G-CSF, IL-12, IL-15, 
IL-7, and IL-1ǃ were measured by Lincoplex assay, IFN-ǂ was measured by bead array, and 
TGF-ǃ1 was measured by ELISA.  Their analysis revealed statistically significant differences 
between cases and controls in levels of IL-6, IL-8, TNF-ǂ, and MIP-1ǂ, GM-CSF, IL-1ǃ (all P < 
0.0001) and IL-1ǂ (P = 0.02). However, it should be noted that this study was intentionally 
designed to explore differences between the extremes of the immunological spectrum. Thus, 
differences between these groups are likely to be biased away from the null (upward) in 
comparison to the general population. All six of these studies failed to concurrently evaluate 
potential confounders, and with the possible exception of TNF-ǂ, none of their findings have 
been confirmed by other studies.  
Unlike the other studies, Hong et al. (Hong, Kim et al. 2010) evaluated several potential 
confounders (parity, menopausal status, smoking, oral contraceptive use, histological findings 
of colposcopic-directed biopsy) in their recently published report of HPV persistence and 
clearance among 160 carcinogenic HPV positive Korean women (normal women or women 
with histologically confirmed mild dysplasia).  While their univariate analysis revealed that 
the number of women who were serum negative for TNF-ǂ was significantly higher in the 
carcinogenic HPV clearance group (N=107) than their persistence group (N=53, P = 0.0363), 
their multivariate logistic regression analysis indicated that none of the four cytokines 
measured (IFN-Ǆ, TNF-ǂ, IL-6, and IL-10) had a significant association with clearance of the 
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carcinogenic HPV infection, pointing to the importance of these factors in future study design. 
In fact, they found that only age was significantly associated with clearance of carcinogenic 
HPV infections (OR, 0.95; 95% CI, 0.92- 0.98; P = 0.001).  
Author & Year
Study source (Origin 
Country)
Immune Marker 
HPV -/+ N (Measurement 
Method)
Major Conclusions
Hildesheim 1997 Kaiser Permanente 
clinics (US)
CellFree IL-2R test kits for sIL-2R 
from plasma recovered by 
centrifugation of peripheral blood
45/60 (Hybrid Capture) No statistically significant association 
between sIL-2R and high risk HPV 
positivity in plasma.
Adam 1999 Centers for Disease 
Control collection 
(United States and 
Panama)
ELISA for Macrophage colony-
stimulating factor (CSF-1) in serum
10/10 (ViraPap + ViraType 
dot blot hybridization 
assay for screen positives)
High-risk HPV infection is associated 
with higher mean serum CSF-1 levels.
Bais 2005 Outpatient GYN clinic 
(The Netherlands)
ELISA for IL-2, IL-4, IL-10, IL-12, 
IFN-Ȗ, TNF-α, sTNFRI, sTNFRII in 
plasma and leucoctye count for 
leucocytes, neutrophils, 
monocytes, and lymphocytes in 
peripheral venous blood
11/10 (GP5+/GP6+ PCR) High-risk HPV infection is associated 
with higher mean plasma IL-2 levels.
Hong 2010 University hospital 
and women's health 
center (Korea)
ELISA for  IFN-Ȗ, IL-6, IL-10, TNF-
α in serum
0/160* (Hybrid Capture 2) Based on univariate analysis, the 
number of women that were serum 
negative for TNF-α  was significantly 
higher in the high risk HPV clearance 
group than the persistence group (P = 
0.0363). Based on multivariate logistic 
regression,  none of the 4 cytokines had 
a significant association with clearance 
of the high risk HPV infection. Only age 
was significantly associated with 
clearance of the high risk HPV infection 
(OR, 0.950; 95% confidence interval, 0.92-
0.98; P = 0.001).**
Kemp 2010 Population-based 
cohort (Costa Rica)
Linco-plex assay for IL-2, IL-4, IL-
5, IL-6, IL-8, IL-10, IL-13, IL-17, IL-
1α, IFN-Ȗ, GM-CSF, TNF-α, MCP-
1, MIP-1α, IP-10, RANTES, eotaxin, 
G-CSF, IL-12, IL-15, IL-7, and IL-
1ȕ; ELISA for TGF-ȕ1; single 
analyte in a bead array for IFN-α.
50/50 (MY09/11 PCR, dot 
blot hybridization for 
genotyping)
Persistent HPV infection in older women 
with evidence of immune deficit is 
associated with an increase in systemic 
inflammatory cytokines and weak 
lymphoproliferative responses.
Abike 2011 GYN Department 
(Turkey)
ELISA for neopterin in serum 78/44 (Amplisense HPV 
multiplex PCR typing kit)
Neopterin levels were lower in women 
with HPV than women without HPV.
Baker 2011 Population-based 
cohort (Costa Rica)
Millipore Multiplex Bead Assay for 
adiponectin, resistin, tPAI-1,  HGF, 
TNF-α, leptin, IL-8, sVCAM-1, 
sICAM-1, sFas, MIF in PBMCs 
from heparinized blood
50/50  (MY09/11 PCR, dot 
blot hybridization for 
genotyping)
Resistin, sFas, IL-8, and TNA-α were 
elevated in women with persistent HPV 
infection compared to HPV-negative 
women.
* Compared HPV persistence and clearance. Thus, all were HPV-positive at baseline. **Adjusted for age, parity, menopause, oral contraception, 
histological findings of colposcopic-directed biopsy, and cytokines. Abbreviations: US = United States, HPV = human papillomavirus, DNA = 
deoxyribonucleic acid, GYN = Gynecology, PCR = polymerase chain reaction, ELISA = enzyme-linked immunosorbent assay, PBMCs= peripheral 
blood mononuclear cells 
 
Table 1. Studies of circulating immune markers in plasma and serum. 
Local Immune Marker Secretions in the Cervix. It is believed that measurement of 
cytokines in cervical secretions may better reflect local cytokine production relevant to 
cervical carcinogenesis than circulating cytokines. Currently, seven studies that met our 
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inclusion criteria have measured immune responses in cervical secretions (Table 2). Unlike 
the studies of circulating cytokines above, most of these studies have tested for a broad 
range of HPV types, although one (Guha and Chatterjee, 2009) only tested for carcinogenic 
HPV types using the Hybrid Capture 2 assay, and another only analyzed results for women 
with carcinogenic HPV infection compared to women without carcinogenic HPV infection 
(Marks, Viscidi et al. 2011). Scott et al. (Scott, Stites et al. 1999) evaluated RNA expression of 
IL-4, IL-12, IFN-Ǆ, and TNF and found that a T-helper type 1 (TH1) cytokine expression 
pattern (as defined by IFN-Ǆ and TNF positivity and IL-4 negativity, with variable IL-12 
expression) preceded HPV clearance. Crowley-Nowick et al. (Crowley-Nowick, Ellenberg et 
al. 2000) measured IL-2, IL-10, and IL-12 cytokine levels in HIV-positive and HIV-negative 
adolescents recruited from 16 clinical care settings in 13 US cities. Crowley-Nowick et al. 
found that HPV-positive girls had higher IL-12 concentrations compared to HPV-negative 
women (P = 0.01). Race, age, SIL status, smoking, other vaginal infections, and CD4 count 
were considered as potential confounders, but all were dropped out of the backwards 
regression model. Tjiong van der Vange et al. (Tjiong 2001) evaluated IL-12p40, IL-10, TGF-
ǃ1, TNF-ǂ, and IL-1ǃ levels by HPV status in CIN patients referred to an outpatient 
gynecology department. Similar to Crowley-Nowick et al., Tjiong van der Vange et al. found 
higher levels of IL-12 in HPV-positive compared to HPV-negative patients (P=0.04) (Tjiong 
2001). However, no attempts were made to adjust for potential confounders. Unlike 
Crowley-Nowick et al. (Crowley-Nowick, Ellenberg et al. 2000) and Tjiong van der Vange et 
al. (Tjiong 2001), Gravitt et al. (Gravitt, Hildesheim et al. 2003) found no statistical 
differences in IL-10 and IL-12 concentrations by HPV-positivity versus HPV-negativity in 
women selected from a population-based cohort study in Guanacaste, Costa Rica, after 
adjusting for stage of menstrual cycle, recent oral contraceptive use secretion volume, and 
pH. Lieberman et al. (Lieberman, Moscicki et al. 2008) used a multiplex immunoassay kit to 
measure IL-1ǃ, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p40/p70), IL-13, IFN-Ǆ in young 
women attending a family-planning clinic or university health center, or their friends. 
Although no significant differences were observed for women with incident or persistent 
HPV infections compared to women without HPV, there was some suggestion that IL-1ǃ 
and IL-13 levels were reduced in women with incident or persistent HPV infections and that 
IL-6 and IL-2 levels were reduced in women with incident infections. Guha et al. (Guha and 
Chatterjee 2009) measured IL-1ǃ, IL-6, IL-10, and IL-12 cytokine levels in commercial sex 
workers or spouses of HIV-positive men coming in for an HIV test. After taking HIV status 
into account, IL-1ǃ, IL-10, and IL-12 seemed to be elevated in HPV-positive women 
compared to HPV-negative women. IL-6 was also higher in HPV-positive women compared 
to HPV-negative women (P ≤ 0.0004). After stratifying by HIV status, however, IL-6 was 
only notably elevated in in women positive for both HPV and HIV, making the association 
with HPV less clear. This study also evaluated cytokine levels by abnormal versus normal 
cervical cytology and found that only IL-6 was related to abnormal cytology (P = 0.03). 
Finally, a recent study by Marks et al. (Marks, Viscidi et al. 2011) evaluated 27 different 
cytokines in a multiplex assay in cervical secretions from 35–60-year-old women attending 
outpatient obstetrics and gynecology clinics for routine examination. Similar to Gravitt et al. 
(Gravitt, Hildesheim et al. 2003) and Lieberman et al. (Lieberman, Moscicki et al. 2008), this 
study found no association between IL-12p70 and HPV status. However, IL-5 (p = 0.03), IL-9 
(p = 0.04), IL-13 (p = 0.01), IL-17 (p = 0.003), EOTAXIN (p = 0.04), GM-CSF (p = 0.01), and 
MIP-1ǂ (p = 0.005) levels were elevated in women with carcinogenic HPV infection 
compared to those without carcinogenic HPV. In addition, T-cell and pro-inflammatory 
cytokines tended to be correlated with EOTAXIN in women with carcinogenic HPV, while 
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they were correlated with IL-2 in women without carcinogenic HPV. The authors conclude 
that this shift from IL-2 to EOTAXIN may reflect a shift away from antigen-specific adaptive 
responses toward innate responses. 
Author & Year
Study source        
(Origin Country)
Immune Marker 
Measurement
HPV -/+ N 
(Measurement Method)
Major Conclusions
Scott 1999 Family planning clinics 
(US)
RT-PCR of cDNA from total 
RNA for IL-4, IL-12, IFN-Ȗ, 
TNF
13/22 (MY09/11 PCR) HPV-positive subjects (especially those 
who cleared) tended to be IFN-Ȗ 
positive, TFN positive, and IL-4 
negative ("Th1 cytokine pattern").
Crowley-Nowick 
2000
16 clinical care 
settings in 13 cities 
(United States)
ELISA for IL-2, IL-10, IL-12 
in Weck-cel sponges
18/20 (PCR) "Coinfection with HIV, human 
papillomavirus, and other STIs predicted 
the highest IL-12 concentrations."*
Tjiong 2001 GYN department (The 
Netherlands)
ELISA for IL-12p40, IFN-Ȗ, 
IL-10, TGF-ȕ1, TNF-α  and 
IL-1ȕ in cervical washes
13/50 ( HPV-16-specific 
PCR;  negative samples  
confirmed by CPI and 
CPIIG) 
IL-12 was more often detected than in 
the HPV-DNA negative CIN patients 
(P=0.04, Chi Square test). No other 
significant associations between 
cytokine levels and the detection of HPV-
DNA were found.
Gravitt 2003 Population-based 
cohort (Costa Rica)
ELISA for IL-10 & IL12 in 
Weck-cel sponges
194/51 (MY09/11 + 
reverse-blot 
hybridization
No significant association between HPV 
and IL-10 or IL-12.**
Lieberman 2007 Family-planning clinic 
or university health 
center or friends (US)
Protein Multiplex 
Immunoassay kits for IL-1ȕ, 
IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12 (p40/p70), IL-13, 
IFN-Ȗ in Merocel sponges
34/33 (PGMY09/11 
PCR)
Although there were no significant 
differences between groups, IL-1ȕ and 
IL-13 seemed to be depressed in women 
with incident or persistent HPV 
infections. IL-6 and IL-2 also seemed to 
be depressed in women with incident 
infections.
Guha 2009 Commercial sex 
workers or spouses of 
HIV+ men (India)
ELISA for IL-1ȕ, IL-6, IL-10, 
IL-12 in lavage samples
28/17 (Hybrid Capture 
2)
Taking HIV status into account, IL-1ȕ, 
IL-10, and IL-12 seemed elevated in 
HPV+ vs. HPV- women. IL-6 seemed 
elevated when HIV was not taken into 
account (16.6 vs. 4.5 pg/ml, p≤0.0004), 
but otherwise was only notably elevated 
in women positive for both HPV and 
HIV.
†
Marks 2011 Outpatient OB/GYN 
clinics (US)
Bio-Rad multiplex assay for 
BASICFGF, EOTAXIN, 
GCSF, GMCSF, IFN-Ȗ, IL-
1ȕ, IL-1ra, IL-2, IL-4, IL-5, IL-
6, IL-7, IL-8, IL-9, IL-10, IL-
12p70, IL-13, IL-15, IL-17, IP-
10, MCP-1, MIP-1α, MIP-1ȕ, 
PDGF-BB, RANTES, TNF-α, 
VEGF in Merocel sponges
44/34 (Roche HPV 
Linear Array)
Carcinogenic HPV associated with 
elevated IL-5, IL-9, IL-13, IL-17, 
EOTAXIN, GM-CSF, and MIP-1α levels 
and a shift from IL-2 to EOTAXIN 
compared to no carcinogenic HPV, 
possibly reflecting a shift away from 
antigen-specific adaptive responses 
toward innate responses.
*Considered potential confounders, but all were dropped through backwards modeling. †Stratified by HIV status, but did not evaluate 
additional confounders.  Abbreviations: US = United States, HPV = human papillomavirus, HIV = human immunodeficiency virus, CIN = 
cervical intraepithelial neoplasia, GYN = gynecology, OB/GYN = obstetrics and gynecology, PCR = polymerase chain reaction, qRT-PCR 
= quantitative reverse transcriptase PCR, STI = sexually transmitted infection
 
Table 2. Studies of immune markers in cervical secretions. 
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There is little consistency in the cytokines evaluated in these seven studies, but where there 
is overlap, the results tend to be contradictory. For example, one study found evidence that 
IL-6 levels were reduced in women with incident HPV infections (Lieberman, Moscicki et al. 
2008), while another found that IL-6 levels tended to be elevated in HPV-positive women 
(Guha and Chatterjee 2009). Similarly, one study found no evidence that IL-12 levels varied 
by HPV status (Gravitt, Hildesheim et al. 2003), while two others (Crowley-Nowick, 
Ellenberg et al. 2000; Tjiong, van der Vange et al. 2001) observed higher levels of IL-12 in 
HPV-positive versus HPV-negative women. In addition, results from the study by Guha et 
al. (Guha and Chatterjee 2009) suggested a tendency toward increased levels of IL-1ǃ in 
HPV-positive women versus HPV-negative women, while the results from Lieberman et al. 
(Lieberman, Moscicki et al. 2008) showed a trend toward decreased levels of IL-1ǃ in women 
with incident or persistent HPV infection compared to HPV-negative women. These 
inconsistencies are not yet resolved. 
Cytokine Responses in Patient-derived PBMCs. There is evidence that cell-mediated 
immune responses play an important role in the control of HPV infections. Cell-mediated 
immune responses are regulated by T lymphocytes [T-helper (Th) lymphocytes and 
cytotoxic lymphocytes (CTLs)] in cooperation with antigen-presenting cells such as 
monocytes and dendritic cells. These cells all are modulated by and release cytokines that 
can influence one another's synthesis. Characterization (including quality and quantity) of 
lymphocytes directed against HPV epitopes has been examined with the goal of providing 
insights into the clinical outcomes of HPV-positive patients. To this end, analyses of 
cytokines and concurrent lymphoproliferative and CTL responses in patient-derived 
peripheral blood mononuclear cells (PBMCs), T-cell fractions isolated from PBMCs or whole 
blood cultures after stimulation with several antigens and/or HPV peptides has been 
evaluated in 10 publications (Table 3).   
Tsukui et al. (Tsukui, Hildesheim et al. 1996) was one of the first to measure IL-2 levels in 
culture supernatants of PBMCs stimulated with predominantly 15mer overlapping peptides 
from HPV-16 E6 and E7 oncoproteins. The HPV early proteins E2, E6 and E7 are among the 
first of proteins that are expressed in HPV-infected epithelia. Stimulation with influenza 
served as a specificity control, and stimulation with phytohemagglutinin (PHA) served as a 
positive control since it is known to activate lymphocytes and induce rapid cell proliferation 
as well as lead to the release of inflammatory and immune cytokines. While the report itself 
focused on associations with IL-2 and disease progression, the study included both HPV 
typing data and IL-2 response data for each subject included in the study. Interestingly, by 
using the data presented in the paper for statistical calculation, we found that IL-2 levels 
were significantly increased in a group of 32 HPV positive healthy women and women with 
LSIL compared to a group of 51 HPV negative healthy women and women with LSIL 
(P=0.006). Among 18 women with HSIL with HPV typing and adequate IL-2 data, only 2 
women had positive IL-2 levels (1 HPV positive, 1 HPV negative).  
Several other studies also attempted to evaluate IL-2 levels in a similar manner. deGruijl et 
al. (de Gruijl, Bontkes et al. 1998) examined IL-2 reactivity in PBMCs stimulated with HPV16 
E7 and sorted by anti-CD4 or anti-CD8 antibodies. They found that positive CD4+ T helper 
cell IL-2 reactivity was restricted to patients infected by HPV16 and related types and that 
reactivity was strongly associated with HPV persistence. Further, women with cervical 
carcinoma showed IL-2 responses at a significantly reduced rate [7 of 15 (47%); P = 0.014].  
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Author & Year
Study source        
(Origin Country)
Immune Marker 
Measurement
HPV -/+ N       
(Measurement Method)
Major Conclusions
Tsukui 1996 Kaiser Permanent or 
Simmons Cancer 
Center (US)
IL-2 was measured by 
radioimmunoassay in  culture 
supernatants of PBMCs from 
whole blood that were 
stimulated with 15mer HPV16 
peptides to E6 and E7, or 
stimulated with FLU or PHA
56/40 (ViraPap:  Hybrid 
Capture with HPV-16-
specific Hybrid Capture for 
+ samples. Tumors:  
GP5+/GP6+ PCR)
IL-2 is signficantly increased in healthy 
HPV+ women and HPV+ women with 
LSIL . Few women with HSIL or cancer 
have detectable IL-2 levels. 
Kadish 1997 Colposcopy clinic 
(US)
Measured lymphocyte 
proliferation in HPV16 E6 and 
E7 peptide stimulated cultures 
of PBMCs from heparinized  
blood 
26/51 (PCR and Southern 
Blot assay; typing by dot 
blot for 39 types)
Lymphoproliferative responses to 
specific HPV16 E6 and E7 peptides are 
significantly associated with the 
clearance of HPV infection.
de Gruijl 1998 Non-intervention 
cohort follow-up 
study of patients 
with cervical 
dysplasia plus follow-
up study of HPV-
positive women with 
normal cervical 
cytology 
(Netherlands)
IL-2 was measured by IL-2 
bioassay in  culture 
supernatants of PBMCs from 
heparinized blood that were  
stimulated with 14 different 
20mer HPV16 peptides to E7, or 
stimulated with PHA; T cell 
subsets were depleted by 
magnetic bead sorting and anti-
CD4 and anti-CD8 antibodies
15/51 (GP5+/GP6+ PCR) Positive CD4+ T helper  cell IL-2 
reactivity was restricted to patients 
infected by HPV-16 and related types 
and showed a strong association with 
viral persistence. Women with cervical 
carcinoma showed IL-2 responses at a 
significantly reduced rate [7 of 15 
(47%); P = 0.014].
Bontkes 1999 Non-intervention 
cohort follow-up 
study of patients 
with cervical 
dysplasia 
(Netherlands)
IL-2 was measured by IL-2 
bioassay in culture 
supernatants of PBMCs from 
heparinized blood that were 
stimulated with HPV16 N-
terminal and C-terminal E2 
protein fragments or with PHA.
22/52 (GP5+/GP6+ PCR) HPV16 infection was not associated 
with IL-2 responsiveness against the N-
terminal domain of E2, but HPV 
clearance was associated with IL-2 
responsiveness against the C-terminal 
E2 domain
de Gruijl 1999 Non-intervention 
cohort follow-up 
study of patients 
with cervical 
dysplasia 
(Netherlands)
IL-2 was measured by IL-2 
bioassay in culture 
supernatants of PBMCs from 
heparinized blood that were 
stimulated with HPV16 L1-VLP 
or synthetic L1-derived 15-mer 
peptides P1 (amino acids 311-
325) and P2 (amino acids 321-
335), or stimulated with PHA; T 
cell subsets were depleted by 
magnetic bead sorting and anti-
CD4 or CD8 antibodies. HPV-
16 L1-VLP-speciic plasma IgG 
was measured by ELISA.
15/49 (GP5+/GP6+ PCR) IgG responses were significantly 
associated with HPV16 persistence but 
CD4 T helper IL-2 responses were 
significantly associated with both HPV 
clearance and  persistence. Neither cell-
mediated nor humoral immune 
responses against HPV16 L1 seemed 
adequate for viral control.
Abbreviations:  US = United States, HPV = human papillomavirus, DNA = deoxyribonucleic acid, GYN = Gynecology, PCR = polymerase chain 
reaction, ELISA = enzyme-linked immunosorbent assay, PBMCs= peripheral blood mononuclear cells, FLU= influenze, PHA = 
phytohemagglutinin, LSIL = low grade squamous intraepithelial lesion, HSIL = high grade squamous intraepithelial lesion, mCTLp= memory 
cytotoxic T-cell precursor 
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Author & Year
Study source        
(Origin Country)
Immune Marker        
Measurement
HPV -/+ N       
(Measurement Method)
Major Conclusions
Bontkes 2000 Non-intervention 
cohort follow-up 
study of patients with 
cervical dysplasia 
(Netherlands)
HPV16-specific mCTLp activity 
was measured in cultured PBMCs 
from heparinized blood stimulated 
with both HPV16 E6 and E7 
peptides. IL-2 was measured by 
IL-2 bioassay in culture 
supernatants of PBMCs that were 
stimulated with 14 different 20mer 
HPV16 peptides to E7, or 
stimulated with PHA.
11/20 (GP5+/GP6+ PCR) mCTLp activity was significantly 
associated with persistent HPV16 
infection but not observed in HPV 
negative women or women with viral 
clearance. HPV 16 E7-specific mCTLp 
activity was associated with previously 
published IL-2 release in response to 
HPV 16 E7-derived peptides at the end 
of follow-up.
Molling 2007 Non-intervention 
cohort follow-up 
study of patients with 
cervical dysplasia 
(Netherlands)
Cultured PBMCs taken from 
heparinized blood were 
stimulated with 14 different 20mer 
HPV16 E7 peptides or with PHA. 
IL-2 levels were determined by 
bioassay. CTL activity 
determined by chromium release 
assay. iNKT and Treg counts 
were measured by FACS. FoxP3 
staining was performed using an 
available kit. Lymphocytes were 
characterized by staining with 
monoclonal antibodies.
2458 (GP5+/GP6+ PCR 
and type specific PCR 
for 27 types)
Treg frequencies significantly 
increased in women with persistent 
HPV16 infection. Treg frequencies were 
increased in patients who had 
detectable HPV16 E7 specific IL-2 
producing T-helper cells, suggesting 
HPV may affect Treg development. No 
evidence that iNKT cells affect  
persistence of HPV16 infection.
Seresini 2007 Healthy donors and 
women with cervical 
lesions (Italy)
CD4+ T cells were purified from 
cultured PBMCs from perifpheral 
blood stimulated with HPV18 E6 
peptides or PHA and CTL 
activity was measured by 
chromium release assay as well as 
IL-4, IL-5, IL-10 and IFN-Ȗ levels 
using cytometric bead array kits. 
The immune infiltrates in  cervical 
lesions were also evaluated.
25/37 (Hybrid Capture 2 
and typing by reverse 
hybridization assay)
One or more HPV18 E6 peptides were 
observed to be able to induce a 
response in 40-50% of the women 
evaluated. Response percentages 
increased to 80-100% when HPV18+ 
women alone were considered. Levels 
of IFN-Ȗ released were shown to predict 
HPV persistence and/or disease relapse 
after surgery. A higher number of 
infiltrating CD4(+) and T-bet(+) T cells 
were observed in the lesions which 
correlated with favorable clinical 
outcomes. 
Sharma 2007 Outpatient department 
or cancer clinic (India)
IL-2,  IFN-Ȗ, IL-4, and IL-10 was 
measured by ELISA in cultured 
PBMCs from heparinized blood 
stimulated with PHA
30/84 (HPV16 and HPV 
18 PCR)
Increasing levels of IL-4 and IL-10 
levels were significantly associated  
with HPV infection. Decreasing levels 
of IL-2 and  IFN-Ȗ were associated with 
HPV status. 
Kemp 2010 Population-based 
cohort (Costa Rica)
Linco-plex assay for  IL-6, IL-8, 
TNF-α, MIP-1α in unstimulated 
and PHA stimulated PBMCs
50/50 (MY09/11 PCR, 
dot blot hybridization 
for genotyping)
IL-6, TNF-α, MIP-1α levels were 
significantly higher in unstimulated 
PBMCs from HPV+ and HPV- women;  
IL-6, IL-8, TNF-α and MIP-1α levels 
were significantly lower in PHA 
stimulated PBMCs between HPV+ and 
HPV- women
Abbreviations:  US = United States, HPV = human papillomavirus, DNA = deoxyribonucleic acid, GYN = Gynecology, PCR = polymerase chain 
reaction, ELISA = enzyme-linked immunosorbent assay, PBMCs= peripheral blood mononuclear cells, FLU= influenze, PHA = 
phytohemagglutinin, LSIL = low grade squamous intraepithelial lesion, HSIL = high grade squamous intraepithelial lesion, mCTLp= memory 
cytotoxic T-cell precursor  
Table 3. Part 2. Cytokine Responses in Patient-derived PBMCs. 
These findings are consistent with Tsukui et al. (Tsukui, Hildesheim et al. 1996) and suggest 
that IL-2 responsiveness may differ by cytological and/or disease stage.  In 1999, deGruijl et 
al. (de Gruijl, Bontkes et al. 1999) again evaluated IL-2 levels, as well as IgG responses, in 
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this same population. This time, they used HPV16 L1-VLP or synthetic L1-derived 15-mer 
peptides P1 (amino acids 311-325) and P2 (amino acids 321-335) to stimulate the PBMCs and 
sorted them as before. Importantly, they found IgG responsiveness was significantly 
associated with HPV16 persistence alone, but that CD4 T helper IL-2 responsiveness was 
significantly associated with both HPV clearance and persistence. Further, they reported 
that neither cell-mediated nor humoral immune responses against HPV16 L1 seemed 
adequate for viral control. In another publication, this group took their study one step 
further and measured IL-2 levels in response to HPV E2 N-terminal and C-terminal protein 
fragments (Bontkes, de Gruijl et al. 1999).  They reported that HPV16 infection was not 
associated with IL-2 responsiveness against the N-terminal domain of E2, but HPV clearance 
was associated with IL-2 responsiveness against the C-terminal E2 domain. The following 
year, Bontkes et al. (Bontkes, de Gruijl et al. 2000) evaluated HPV 16 E6- and E7-specific 
memory cytotoxic T-cell precursor (mCTLp) activity in the same cohort of patients with 
cervical dysplasia. They found that activity was significantly associated with persistent 
HPV16 infection but not observed in HPV negative women or women with viral clearance. 
Kadish et al. (Kadish, Ho et al. 1997) had previously observed a similar phenomenon.  
Subjects with positive lymphoproliferative responses to E6 and/or E7 peptides were more 
likely to be HPV negative at the same clinic visit than were nonresponders (P = 0.039). 
Subjects who were negative for HPV and those with a low viral load were also more likely 
to respond than were those with a high viral load (P for trend = 0.037). These data suggest 
that lymphoproliferative responses to specific HPV 16 E6 and E7 peptides appear to be 
associated with the clearance of HPV infection. 
In 2007, three additional reports evaluating patient-derived PBMCs were published. Sharma 
et al. (Sharma, Rajappa et al. 2007) focused on IL-2, IFN-g, IL-4, and IL-10 levels in PBMCs 
stimulated with PHA. They observed that increasing levels of IL-4 and IL-10 levels were 
significantly associated with HPV infection and that decreasing levels of IL-2 and IFN-Ǆ 
were associated with HPV status. Seresini et al. (Seresini, Origoni et al. 2007) measured 
lymphoproliferative responses and IL-2, IFN-g, IL-4, and IL-10 levels in PBMCs stimulated 
not with HPV16 peptides, but rather with HPV18-specific E6 peptides. Their analyses 
revealed that one or more HPV18 E6 peptides were able to induce a response in 40-50% of 
the women evaluated. Response percentages increased to 80-100% when HPV18-positive 
women alone were considered. Levels of IFN-Ǆ released were also shown to predict HPV 
persistence and/or disease relapse after surgery. In addition, they showed that a higher 
number of infiltrating CD4(+) and T-bet(+) T cells in lesions correlated with favorable 
clinical outcomes.  Finally, Molling et. al. (Molling, de Gruijl et al. 2007) evaluated cultured 
PBMCs again stimulated with 14 different 20mer HPV16 E7 peptides or with PHA and 
measured both IL-2 levels and CTL activity. Importantly, they also measured invariant 
natural killer T-cells (iNKT) and FoxP3+ regulatory T cells (Tregs) levels by flow cytometry 
(FACSCalibur). While iNKT cells did not appear to be associated with HPV persistence, 
Treg frequencies were significantly increased in women with persistent HPV16 infection; 
and the Tregs were significantly more common in women who had detectable HPV16 E7 
specific IL-2 producing T-helper cells. These data suggest that HPV infection may affect 
Treg development – a finding that opens the door for a whole new avenue of research 
related to HPV-related immune research. 
Immune Markers in Cervical Tissues  PBMC responses and circulating or secreted 
cytokines can be useful indicators of immune response, but the best indications may come 
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from the actual site of interaction between HPV infection and the immune system: tissue. A 
number of studies have attempted to measure immune markers in HPV-positive compared 
to HPV-negative women in different ways. Among studies included in this review, these 
markers fall into three major categories: immune presentation molecules, cytokines or 
cytokine receptors, and immune cells. 
Several studies used immunohistochemistry (IHC) to stain for major histocompatibility 
complex (MHC) proteins in cervical tissue (Table 4). MHC class I molecules present 
endogenous antigens (cytoplasmic proteins) to cytotoxic (CD8+) T cells and are typically 
present on all nucleated cells (Murphy, Travers et al. 2011). In contrast, MHC class II 
molecules present exogenous antigens from outside the cell to helper (CD4+) T cells and are 
typically present only on antigen presenting cells, such as dendritic cells and macrophages. 
Thus, normal cervical epithelial cells should be MHC class I positive and MHC class II 
negative. In humans, MHC class I consists of major human leukocyte antigens (HLA) A, B, 
and C and minor antigens E, F, and G, while MHC class II consists of HLA-DM, -DO, -DP, -
DQ, and -DR. 
Using a polyclonal stain specific for HLA-A, -B and -C heavy chains in formalin-fixed, 
paraffin-embedded (FFPE) tissue from biopsies and resection specimens from women with 
CIN1-3 or cancer, Cromme et al. (Cromme, Meijer et al. 1993) found that normal MHC class 
I expression, defined positive staining in ≥75% of cells, was reduced in women with HPV16, 
18, or 31 infection versus HPV-negative women (p=0.04). MHC class II expression, as 
measured through a polyclonal HLA-DR antigen stain, was also altered, with normal 
staining (<25% positively stained cells) in 42% of women with HPV16, 18, or 31 infection 
versus 64% of HPV-negative women. This alteration was not statistically significant, 
however (p=0.14). Gonclaves el al (Goncalves, Le Discorde et al. 2008) also examined MHC 
class I expression in FFPE biopsy blocks, but in women with normal through cancerous 
histology. They found that HLA-A/B/C expression was not significantly elevated in HPV-
positive compared to HPV-negative women (OR, 2.29; 95% CI, 0.77- 11.00; P = 0.14). 
Strangely, HPV16/18 infection was inversely associated with HLA-A/B/C expression (OR, 
0.12; 95% CI, 0.02- 0.79; P = 0.04), but as reported, it was unclear whether this association 
was based on comparison to HPV-negative women, or a combination of both HPV-negative 
women and women with HPV infections other than HPV16 and 18. HLA-E expression 
tended to be increased in HPV-positive versus HPV-negative women (OR, 3.83; 95% CI, 
0.49-30.10; P = 0.22), especially for HPV16/18 infections (OR, 11.25; 95% CI: 2.32-55.47; P = 
0.003). Similarly, Dong et al. (Dong, Yang et al. 2010) stained for HLA-G in FFPE blocks from 
CIN1-3 patients and found higher HLA-G expression in HPV16/18-positive patients than 
HPV16/18-negative patients (P = 0.02). 
In addition to interaction with an antigen MHC complex, T-cells require costimulation with 
an antigen nonspecific molecule to be full activated. T cells that encounter antigen MHC 
complex without costimulation may be come anergic and thus tolerant to the presence of 
HPV. To investigate this possibility, Ortiz-Sanchez et al. (Ortiz-Sanchez, Chavez-Olmos et 
al. 2007) evaluated expression of the CD80 and CD86 MHC class II costimulatory molecules 
through immunohistochemistry (IHC), quantitative reverse transcriptase PCR (qRT-PCR), 
and RNA in situ hybridization (ISH) in FFPE biopsies from histologically normal HPV-
negative women and HPV16-positive women with LSIL. They found that CD86, but not 
CD80, was expressed in all HPV-negative normal cervical epithelial samples, while CD86  
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Author & Year
Study source        
(Origin Country)
Immune Marker 
Measurement
HPV -/+ N       
(Measurement Method)
Major Conclusions
Cromme 1993 Oncological GYN 
oupatient department 
(Netherlands)
IHC for MHC-I & MHC-II 
expression in FFPE tissue from 
biopsies & resection 
specimens
14/107 (GP 5/6 PCR + TS 
PCR for HPV6, 11, 16, 18, 31, 
33; RNA ISH for HPV16 E7)
Normal MHC-I expression reduced in 
women with HPV16, 18, or 31 vs. HPV-
negative women (p=0.04). MHC-II 
expression was also altered with  
HPV16/18/31, but not significantly.
Fernandes 2005 Outpatient GYN Clinic 
(Brazil)
Double-sandwich ELISA for 
IFN-Ȗ, TNF-α, IL-10 in snap 
frozen cervical biopsies
0/42 (GP5/6, MY09/11, 
HPV16E7.667/HPV16E7.774, 
HPV18E7.696/HPV18E7.799 
PCRs)*
HPV16 associated with higher IL-10 and 
IFN-Ȗ intralesional levels than other HPV 
types, but HPV18 was associated with 
reduced TNF-α and INF-Ȗ levels. Thus, 
immune response may vary by HPV type.
Ortiz-Sanchez 2007 Women undergoing a 
routine hysterectomy 
due to uterine 
myomatosis and 
women with LSIL 
(Mexico)
IHC, qRT-PCR, ISH for CD80 
and 86; IHC for IL10 in FFPE 
biopsies
30/30 (MY09/11 and p16-1 
and p16-2R primer PCR. HPV 
typing by sequence 
comparison. Only the HPV-
16 samples included in  
CD86 expression analysis.)
CD86 expression was decreased in patients 
with HPV16 positive LSIL versus normal 
women, independent of IL-10. Expression 
of CD86 on normal cervical keratinocytes 
could indicate the ability to activate 
cytotoxic T cells, while the shut-off of this 
molecule in HPV-16 positive lesions could 
be a mechanism for evading host immune 
surveillance, resulting in the persistent 
HPV infection and probable progression of 
cervical lesions. 
Song 2007 OB/GYN clinic 
(Republic of Korea)
qRT-PCR for IL-6, IL-10, IFN-Ȗ, 
TNF-α in frozen tissue 
biopsies
0/67 (Hybrid Capture 2  + 
HPV DNA Chip)*
IFN-Ȗ was significantly associated with 
HPV-16 E6, E7, and high-risk HPV viral load 
among HPV-positive women.**
Bermudez-Morales 
2008
Instituto Nacional de 
Cancerolog ı´a 
(National 
Cancerology 
Institute, Mexico)
RT-PCR for IL-10 in cervical 
scraping and biopsies (storage 
not specified)
28/47 (PCR-RFLPs) Strong association between HPV positivity 
and IL10 mRNA levels
Butsch Kovacic 2008 The ASCUS/LSIL 
Triage Study for 
Cervical Cancer 
(ALTS) trial (US)
Visual counting of 
lymphocytes, neutrophils, 
macrophages, plasma cells, 
and eosinophils in 3 H&E 
sections per biopsy (stromal 
and epithelial sections of 
hematoxylin and eosin stain 
slides from FFPE biopsy tissue 
evaluated)
228/288 (Hybrid Capture 2 
and PCR)
These data suggest that cervical 
inflammation varies with type of human 
papillomavirus infection, risk of persistence 
and progression and HPV cofactors.**
*Evaluated cytokine expression by HPV type in HPV-positive women. **Study adjusted for confounding factors in regression models. †Compared 
HPV persistence and clearance. Thus, all were HPV-positive at baseline. Abbreviations: HPV = human papillomavirus, CIN = cervical intraepithelial 
neoplasia, FFPE = formalin-fixed paraffin-embedded, GYN = gynecology, ISH = in situ hybridization, IHC = Immunohistochemistry, OB/GYN = 
obstetrics and gynecology, qRT-PCR = quantitative reverse transcriptase PCR, STI = sexually transmitted infection, TIL = tumor infiltrating 
lymphocytes, RFLPs= Restriction Fragment Length Polymorphisms, ASCUS = Atypical Squamous Cells of Undetermined Significance, LSIL = low 
grade squamous intraepithelial lesion, HSIL = high grade squamous intraepithelial lesion, US = United States
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Author & Year
Study source        
(Origin Country)
Immune Marker 
Measurement
HPV -/+ N       
(Measurement Method)
Major Conclusions
Gonclaves 2008 GYN Reference 
Services (Brazil)
IHC for HLA-A/B/C and 
HLA-E in RNA from FFPE 
biopsy blocks
19/55 (GP5+/6+, MY09/11, 
HPV16E7.667/ 
HPV16E7.774, 
HPV18E7.696/ 
HPV18E7.799)
Some evidence that HPV infection was 
associated with increased HLA-E 
expression, especially HPV16/18 infection. 
Association with HLA-A/B/C was less 
clear.
Song 2008 OB/GYN clinic 
(Republic of Korea)
qRT-PCR for IL-6, IL-10, IFN-
Ȗ, TNF-α from frozen tissue 
biopsies
0/57 (Hybrid Capture 2)† IFN-Ȗ correlated with high-risk HPV 
clearance.**
Tirone 2009 Women with CIN or 
normal women with 
hysterectomies due to 
uterine myoma (Brazil)
RT-PCR for IFNAR 1, IFNAR 
2, 2'5'OAS, IFN-α from 
cervical tissue biopsies
31/14 (Hybrid Capture 2) Lower IFN-α receptor expression with HPV 
infection.
Brismar Wendel 2010 Healthy volunteers at 
Karolinska Division of 
Obstetrics and 
Gynecology (Sweden)
qRT-PCR for CD3, CD4, CD8, 
CD19, CD27, CCR5, 
CCL5/Rantes, IL-2, IL-4, IL-
10, IL-12a, IL-17a, IL-7R, 
HLA-DRα, IFN-Ȗ, TNF-ȕ, PD-
1, CTLA-4, LAG3, IgA, IgG 
from frozen biopsy of 
ectocervix outside the 
transformation zone
13/11 (Roche Linear Array) HPV not associated with a local 
inflammatory immune response as 
measured by qRT-PCR.
Dong 2010 Department of 
Pathology (China)
IHC for HLA-G and visual 
counting of TILs in 5 high-
power fields from FFPE 
blocks
22/33 (ISH for HPV16 & 18 
in FFPE tissue section)
HLA-G elevated in HPV16/18+ lesions and 
associated with lower TIL counts, 
suggesting inhibition of immune response 
against HPV.
Øvestad 2011 Women refered to a 
hospital for abnormal 
Papanicolaou tests 
(Norway)
IHC for CD4, CD8, CD25, 
from RNA isolated from 
paraffin blocks of punch 
biopsies
CD138, FOXp3
0/45 (AMPLICOR and 
Linear Array)*
HPV16 and related types were correlated 
with lower CD8-positive cell counts in the 
stroma compared to other HPV types.**
*Evaluated cytokine expression by HPV type in HPV-positive women. **Study adjusted for confounding factors in regression models. †Compared 
HPV persistence and clearance. Thus, all were HPV-positive at baseline. Abbreviations: HPV = human papillomavirus, CIN = cervical intraepithelial 
neoplasia, FFPE = formalin-fixed paraffin-embedded, GYN = gynecology, ISH = in situ hybridization, IHC = Immunohistochemistry, OB/GYN = 
obstetrics and gynecology, qRT-PCR = quantitative reverse transcriptase PCR, STI = sexually transmitted infection, TIL = tumor infiltrating 
lymphocytes, RFLPs= Restriction Fragment Length Polymorphisms, ASCUS = Atypical Squamous Cells of Undetermined Significance, LSIL = low 
grade squamous intraepithelial lesion, HSIL = high grade squamous intraepithelial lesion, US = United States
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expression was lower (73% by IHC) in HPV16-positive LSIL samples. This decrease in CD86 
expression in HPV-positive women could represent and immune evasion mechanisms 
through the down-regulation of costimulatory molecules. 
The next major category of immune markers measured in cervical tissue includes cytokines 
and their receptors. In addition to testing for MHC costimulatory molecules, Ortiz-Sanchez 
et al. (Ortiz-Sanchez, Chavez-Olmos et al. 2007) used IHC to stain for IL-10, which inhibits 
CD86 expression. IL-10 detection was likewise poor in both HPV-negative normal tissue and 
HPV16-positive LSIL tissue, but detection was higher in a high-grade SIL (HSIL) control 
sample. Fernandez et al. 2005 tested for IFN-Ǆ, TNF-ǂ, and IL-10 protein from snap frozen 
cervical biopsies from HIV-positive or HIV-negative LSIL and HSIL patients infected with 
HPV using a double-sandwich ELISA approach. They reported that HPV16 was associated 
with higher IL-10 (P = 0.03) and IFN-Ǆ (P = 0.04) intra-lesional levels than other HPV types, 
but HPV18 was associated with reduced TNF-ǂ (P = 0.009) and INF-Ǆ levels (P = 0.01) 
suggesting that immune responses may vary by the infecting HPV type. 
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The majority of studies measured cytokines with quantitative reverse transcriptase PCR 
(qRT-PCR). Bermudez-Morales et al. (Bermudez-Morales, Gutierrez et al. 2008) found a 
strong association between HPV positivity and IL10 mRNA levels, especially for HPV16.  
Song et al. evaluated IL-6, IL-10, IFN-Ǆ, and TNF-ǂ and both HPV16 positivity (Song, Lee et 
al. 2008.) and HPV clearance versus persistence (Song 2008) among women positive for 
carcinogenic HPV. They found that IFN-Ǆ was associated with HPV-16 E6 (OR, 28.20; 95% 
CI, 2.66-299.11) and E7 (OR, 19.62; 95% CI, 2.14-180.25) expression (Song, Lee et al. 2007), as 
well as with clearance of carcinogenic HPV (OR, 8.26; 95% CI: 1.24-54.94) (Song, Lee et al. 
2008.). Tirone et al. (Tirone, Peghini et al. 2009) found some evidence that the IFN-ǂ receptor 
subunits IFNAR 1 and IFNAR 2 were under-expressed in HPV-positive women with CIN1-3 
compared to HPV-negative women with normal through CIN3 histology. Brismar Wendel 
et al. (Brismar Wendel, Kaldensjo et al. 2010) measured a number of different cytokines and 
other immune markers and found no difference between HPV-positive and HPV-negative 
healthy volunteers (22/24 with normal cytology). 
Another major category of immune markers is the immune cells themselves. Two studies in 
this review evaluated infiltrating immune cells in cervical tissue by visually counting the 
cells. Butsch Kovacic et al. (Butsch Kovacic, Katki et al. 2008) counted lymphocytes, 
neutrophils, macrophages, plasma cells, and eosinophils among women with typical 
squamous cells of undetermined significance or LSIL and found that cervical inflammation 
varies with type of HPV infection, as well as risk of persistence and progression. Women 
with carcinogenic HPV infections also had more severe epithelial inflammation and less 
severe stromal inflammation than HPV-negative women. These associations were limited to 
carcinogenic and not the non-carcinogenic HPV types. Dong et al. (Dong, Yang et al. 2010) 
determined that among HPV16/18-positive CIN lesions, moderate to strong HLA-G 
expression was associated with weak immune response, as measured by few tumor 
infiltrating lymphocytes (TIL), whereas weak HLA-G expression was associated with strong 
immune response (high numbers of TIL). HLA-G expression was not associated with TIL in 
HPV-negative women, suggesting that the increased HLA-G expression in HPV-positive 
lesion may reflect an inhibition of immune response against HPV. Brismar Wendel et al. 
(Brismar Wendel, Kaldensjo et al. 2010) used qRT-PCR to measure CD3, CD4, CD8, CD19, 
and CD27 expression but found no difference by HPV status. Finally, Øvestad et al. 
(Ovestad, Vennestrom et al. 2011) used IHC to stain for cell surface marker in biopsies from 
CIN2-3 patients and found that HPV16 and related types were correlated with lower CD8-
positive cell counts in the stroma compared to other HPV types (P = 0.02). 
4. Conclusions and future perspectives 
Taken together, these studies support the role of cell-mediated immune response in HPV-
related carcinogenesis although their findings, particularly for those measuring cytokines, 
are largely inconsistent. There are many potential explanations. There has been a real lack of 
consistency in sample collection methods, cytokine measurement methods and even the 
outcome definitions used for analyses.  
For example, some studies assessed HPV positivity, regardless of timing and/or disease 
state, while others evaluated incident HPV infection or HPV persistence or clearance. 
Further, these studies more than often focused on HPV 16, on carcinogenic HPV types, or 
any HPV type infection together. However, those few studies that did evaluate immune 
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markers by individual HPV type found evidence that immune responses vary by HPV type 
(Fernandes, Gonçalves et al. 2005; Butsch Kovacic, Katki et al. 2008; Ovestad, Vennestrom et 
al. 2011). Thus, HPV type is an important consideration. Moreover, while we chose to focus 
on immune markers’ associations with HPV infection, most of the studies reviewed in this 
chapter predominantly assessed associations between immune markers and disease state 
(LSIL, HSIL, cancer or CIN1-3 and cancer). Ideally, future studies would evaluate 
differences by individual HPV type and better consider the timing of disease. 
There are also other notable differences in the study populations considered by these studies 
(e.g., sample size, young versus old women, inclusion of HIV-positive women). Many 
studies used convenience samples of women. In fact, there is a general lack of consideration 
for factors that could confound or modify both cytokine production and the infectious 
outcomes. Only eight of the 35 studies made any attempt to account for co-factors that may 
influence cytokine level. The importance of adjusting for such potential confounders was 
recently highlighted at an international workshop that addressed best practices for sampling 
techniques and assessment of mucosal immune responses. The workshop identified a 
number of characteristics that should be considered when studying female genital tract 
immunity, including age, race, body mass index, sexually transmitted infections, other 
genital tract infections, vaginal flora, alcohol or substance use, recent immunization, 
pregnancy, phase of menstrual cycle, genital inflammation, recent douching, gynecologic 
procedures, recent intercourse/semen, and contraception (Anderson and Cu-Uvin 2011). 
The number of women included in each study is another important consideration in the 
evaluation of these studies. Twenty-two of the 32 (69%) studies meeting our criteria 
included less than 30 women in one or more groups (e.g., the HPV-positive or HPV-negative 
group). Fifteen (47%) included less than 20 in one or more groups. Small numbers of women 
in the comparison groups can lead to unstable results and may help explain why results for 
individual immune markers are so inconsistent.  
Most studies have measured only a few cytokines, and few have evaluated infiltrating 
immune cells concurrently with cytokines, making it challenging to explore the activation 
pathways of cells involved in the immune response against HPV.  One research group has 
made extensive use of their study population to characterize several aspects of immune 
response as measured in PBMCs (de Gruijl, Bontkes et al. 1998; Bontkes, de Gruijl et al. 1999; 
de Gruijl, Bontkes et al. 1999; Bontkes, de Gruijl et al. 2000; Molling, de Gruijl et al. 2007). 
However, few studies have been so thorough. In fact, more than half of the studies of 
PBMCs (five of nine studies), have come from this same research group with the same study 
population. Additional studies characterizing many aspects of immune response in different 
study populations would help clarify whether the results are broadly applicable. 
Many studies focused on T-helper type 1 (TH1) versus T-helper type 2 (TH2) polarization, 
using a single cytokine (or small group of cytokines) to characterize the T-helper phenotype. 
However, advances in immunology have led to the shift of the TH1/TH2 paradigm to the 
TH1/TH2/TH17/T-reg hypothesis, a multi-lineage commitment from the same T-helper 
precursor cells. TH17 cells, in fact, have been shown to inhibit both TH1 and TH2 cells, and 
therefore are likely to play a critical role in HPV-related immune responses as well. Few 
studies have evaluated TH17 or Treg cells. The recent study by Molling et al. (Molling, de 
Gruijl et al. 2007) is among the few that have measured these cells. Using flow cytometry in 
HPV16 E7 stimulated PBMCs, they determined that Treg frequencies were significantly 
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greater in women with persistent HPV16 infection and in women with detectable HPV16 E7 
specific IL-2 producing T-helper cells, suggesting that HPV infection may affect Treg 
development. These findings may also be supported by tissue-based studies of MHC class II 
expression. Although data are limited, one study found evidence of increased MHC class II 
expression in HPV-positive versus negative patients (Cromme, Meijer et al. 1993), while 
another found reduced expression of the CD86 MHC class II costimulatory molecule (Ortiz-
Sanchez, Chavez-Olmos et al. 2007). It could be hypothesized that HPV upregulates MHC 
class II expression and down-regulates MHC class II costimulatory molecules in order to 
increase T-cell anergy through incomplete signaling. Additional studies are needed to better 
understand these relationships. 
For studies of cervical secretions, the collection method can have a large impact on the 
results. Of the seven cervical secretion studies included in this review, two collected cervical 
secretions through cervicovaginal lavage (Tjiong, van der Vange et al. 2001; Guha and 
Chatterjee 2009), four used Weck-cel® (Crowley-Nowick, Ellenberg et al. 2000; Gravitt, 
Hildesheim et al. 2003) or Merocel® (Lieberman, Moscicki et al. 2008; Marks, Viscidi et al. 
2011) ophthalmic sponges, and one used cytobrush sample suspensions (Scott, Stites et al. 
1999). Cervicovaginal lavages may not be specific enough to the cervix and may overly 
dilute the specimen. Even studies that used ophthalmic sponges tended to use Weck-cel® 
sponges (Gravitt, Hildesheim et al. 2003; Moscicki, Ellenberg et al. 2004), which may not 
provide adequate cytokine recovery, especially compared to Merocel® sponges (Castle et 
al.(Castle, Rodriguez et al. 2004). 
Studies evaluating tissue have seldom considered both stroma and epithelium. In this 
chapter, only two studies examined inflammation in both stroma and epithelium (Butsch 
Kovacic, Katki et al. 2008; Ovestad, Vennestrom et al. 2011). One study found opposite 
inflammatory patterns by HPV status ((Butsch Kovacic, Katki et al. 2008)). This study also 
found that neutrophils tended to be found only in the superficial epithelial layers, whereas 
mononuclear cells were found mainly near the basement membrane, suggesting that 
inflammatory patterns in the stroma and the epithelium may depend on the specific cell 
type. The second study only reported differences by CD8 in the stroma (Øvestad 2011).  
Tissue-based studies of cytokines are also heterogeneous. Only two studies evaluated 
cytokine proteins in tissue (Fernandes, Gonçalves et al. 2005; Ortiz-Sanchez, Chavez-Olmos 
et al. 2007). It is not surprising that few studies have evaluated cytokine proteins in tissue 
since it can be challenging to find an appropriate antibody and optimize the assay. For 
example, antibodies that perform well in western blots may not work for staining since 
staining requires fixation, which can change the confirmation of the cytokine protein, 
thereby preventing antibody binding (Sachdeva and Asthana 2007). Most tissue-based 
studies of cytokines in this review measured RNA expression, but accurate measurement of 
RNA expression requires high quality tissue. If the tissue was not snap frozen immediately 
after surgery and well maintained, endogenous RNases may have degraded the RNA. RNA 
quality is rarely addressed. Although the presence of cytokine transcripts in tissue may be 
meaningful, the absence is not given the short-lived nature of RNA, even for high quality 
tissues (Sachdeva and Asthana 2007).  
To clarify the role of immune response in cervical carcinogenesis, future studies should be 
conducted in well-characterized epidemiologic studies that can address most or all of the 
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characteristics and considerations described above.  Studies should include large numbers 
of women, evaluate a broader spectrum of cytokines/immune markers and measure and 
adjust for potential confounders concurrently. Possible usefulness of tissue microarrays 
and multiplex arrays with well-defined phenotypes should be considered as they are 
likely to make these studies more feasible. Emerging results must be repeated in different 
study populations and specimen types, but are encouraging. Accumulating evidence 
indicates that there is a cell-mediated immune response to HPV. As technologies improve, 
it should become possible to better characterize these responses to distinguish between 
women at risk of developing cervical cancer and women who can effectively resolve their 
HPV infections. 
5. Appendix 1. Search strategy for immune function in cervical 
carcinogenesis 
("humans"[MeSH Terms] AND "female"[MeSH Terms] AND English[lang]) AND ("cervix 
uteri"[MeSH Terms] OR “Uterine Cervical Neoplasms/immunology”[Mesh] OR "Uterine 
Cervical Neoplasms/pathology"[Mesh] OR “Uterine Cervical Neoplasms/blood” [Mesh] 
OR “Cervical Intraepithelial Neoplasia/metabolism”[Mesh] OR “Mucus/metabolism” 
[Mesh]) AND (“Cytokines/blood*”[Mesh] OR “Cytokines/metabolism”[Mesh]  OR 
“Immunity, Innate”[Mesh] OR “Adaptive Immunity”[Mesh] OR “Immunity, 
Cellular”[Mesh] OR “Immunity, Humoral”[Mesh] OR “Immunity, Mucosal”[Mesh] OR 
“Immunity, Innate/immunology”[Mesh] OR “immune infiltrates” OR immunity OR 
"immune response" OR “immune cells” OR "immune cell" OR inflammation OR infiltration 
OR "Lymphocyte Subsets/immunology"[Mesh] OR “TH1 Cells/ immunology” [Mesh] OR 
“TH2 Cells/ immunology” [Mesh]) NOT (mice OR mouse OR “cell line” OR “cell lines” OR  
“mouth” OR “oropharynx” OR “Antiretroviral Therapy, Highly Active"[Mesh] OR “Models, 
Theoretical”[Mesh] OR “Papillomavirus Vaccines/administration & dosage”[Mesh] OR 
“Premature Birth/immunology”[Mesh] OR “HIV Infections/immunology”[Mesh] OR 
“Combined Modality Therapy”[Mesh] OR “Complementary Therapies”[Mesh] OR “Blood 
Vessels/chemistry”[Mesh] OR “Laser Therapy”[Mesh] OR “Labor Stage, 
First/physiology”[Mesh] OR “Foreign-Body Reaction/pathology”[Mesh] OR 
“Postoperative Complications/pathology”[Mesh] OR “Male”[Mesh] OR “Labor, 
Obstetric/metabolism”[Mesh]) 
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